Elucidating the elite: mechanisms of control in HIV-1 infection

Trends in Pharmacological Sciences

Volumn 30, Issue 12, 2009, Pages 631-637

  O'Connell, Karen A ^a   Bailey, Justin R ^a   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAG PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; INTEGRASE INHIBITOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; NEF PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; REV PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70449657764     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.09.005     Document Type: Review

References (80)

1. Shen L., and Siliciano R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122 (2008) 22-28
2. Lambotte O., et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41 (2005) 1053-1056
3. Madec Y., et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19 (2005) 2001-2007
4. Grabar S., et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 23 (2009) 1163-1169
5. Sajadi M.M., et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J. Acquir. Immune Defic. Syndr. 50 (2009) 403-408
6. Pereyra F., et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 200 (2009) 984-990
7. Migueles S.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29 (2008) 1009-1021
8. Hatano H., et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 83 (2009) 329-335
9. Dinoso J.B., et al. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin. Infect. Dis. 47 (2008) 102-104
10. Deacon N.J., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 (1995) 988-991
11. Alexander L., et al. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J. Virol. 74 (2000) 4361-4376
12. Blankson J.N., et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81 (2007) 2508-2518
13. Bailey J.R., et al. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203 (2006) 1357-1369
14. Lamine A., et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 21 (2007) 1043-1045
15. Migueles S.A., et al. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J. Virol. 77 (2003) 6889-6898
16. Miura T., et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82 (2008) 8422-8430
17. Rachinger A., et al. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin. Infect. Dis. 47 (2008) e86-e89
18. Bailey J.R., et al. Transmission of HIV-1 from a patient who developed AIDS to an elite suppressor. J. Virol (2008)
19. Altfeld M., et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17 (2003) 2581-2591
20. Bailey J.R., et al. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J. Infect. Dis. 196 (2007) 50-55
21. Goujard C., et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?. Clin. Infect. Dis 49 (2009) 982-986
22. Nou E., et al. Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors. J. Virol. 83 (2009) 6941-6946
23. Cohen G.B., et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10 (1999) 661-671
24. Fellay J., et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007) 944-947
25. Han Y., et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 22 (2008) 541-544
26. Martin M.P., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39 (2007) 733-740
27. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31 (2002) 429-434
28. O'Connell K.A., et al. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J. Virol. 83 (2009) 5028-5034
29. Fogli M., et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog. 4 (2008) e1000101
30. Alter G., and Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J. Intern. Med. 265 (2009) 29-42
31. Barker E., et al. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 21 (2007) 2363-2365
32. Silvestri G., et al. Understanding the benign nature of SIV infection in natural hosts. J. Clin. Invest. 117 (2007) 3148-3154
33. Mandl J.N., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14 (2008) 1077-1087
34. Sedaghat A.R., et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J. Virol. 82 (2008) 1870-1883
35. Boasso A., and Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin. Immunol. 126 (2008) 235-242
36. Mavilio D., et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203 (2006) 2339-2350
37. Ferre A.L., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113 (2009) 3978-3989
38. Hunt P.W., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197 (2008) 126-133
39. Andrade A., et al. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin. Infect. Dis. 46 (2008) e78-82
40. Sankaran S., et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9860-9865
41. Brenchley J.M., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12 (2006) 1365-1371
42. Goila-Gaur R., and Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5 (2008) 51
43. Wang B., et al. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 312 (2003) 135-150
44. Gandhi S.K., et al. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 82 (2008) 3125-3130
45. Laeyendecker O., et al. The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department. J. Acquir. Immune Defic. Syndr. 48 (2008) 211-215
46. Doria-Rose N.A., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83 (2009) 188-199
47. Li Y., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83 (2009) 1045-1059
48. Scheid J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 (2009) 636-640
49. Bailey J.R., et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80 (2006) 4758-4770
50. Lambotte O., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23 (2009) 897-906
51. Pereyra F., et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197 (2008) 563-571
52. Mahalanabis M., et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83 (2009) 662-672
53. Friedrich T.C., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81 (2007) 3465-3476
54. Emu B., et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79 (2005) 14169-14178
55. Emu B., et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82 (2008) 5398-5407
56. Betts M.R., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
57. Migueles S.A., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3 (2002) 1061-1068
58. Saez-Cirion A., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6776-6781
59. Streeck H., et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 5 (2008) e100
60. Almeida J.R., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204 (2007) 2473-2485
61. Saez-Cirion A., et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182 (2009) 7828-7837
62. Migueles S.A., et al. Defective HIV-specific CD8+ T sell polyfunctionality, proliferation and cytotoxicity are not restored by antiretroviral therapy. J. Virol. (2009)
63. Lichterfeld M., et al. Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 112 (2008) 3679-3687
64. Tilton J.C., et al. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J. Virol 81 (2007) 2713-2725
65. Migueles S.A., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2709-2714
66. Loffredo J.T., et al. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J. Immunol 182 (2009) 7763-7775
67. Valentine L.E., et al. Infection with "escaped" virus variants impairs control of SIVmac239 replication in Mamu-B*08+ macaques. J. Virol (2009)
68. Martinez-Picado J., et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80 (2006) 3617-3623
69. Leslie A.J., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10 (2004) 282-289
70. Brockman M.A., et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81 (2007) 12608-12618
71. Miura T., et al. HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J. Virol. 83 (2009) 3407-3412
72. Goonetilleke N., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206 (2009) 1253-1272
73. Potter S.J., et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81 (2007) 13904-13915
74. Dyer W.B., et al. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology 5 (2008) 112
75. Zaunders J.J., et al. Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J. Virol. 80 (2006) 10162-10172
76. Kaufmann D.E., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8 (2007) 1246-1254
77. van Grevenynghe J., et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat. Med. 14 (2008) 266-274
78. Seddiki N., and Kelleher A.D. Regulatory T cells in HIV infection: who's suppressing what? Curr. HIV/AIDS Rep. 5 (2008) 20-26
79. Chase A.J., et al. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J. Virol. 82 (2008) 8307-8315
80. Nilsson J., et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 108 (2006) 3808-3817